ROR1 and sarcoma: Second, SB modified CAR T cells derived from healthy donors and sarcoma patients targeting IGF1R or ROR1 displayed a specific cytotoxicity and released predominantly IFN-γ, TNF-α and IL-13 cytokines against sarcomas in vitro.